Liu 2016a.

Methods	Study design: Randomised clinical trial Study duration: January 2012 to September 2013 Duration of follow‐up: 2 years Setting: Hospital
Participants	Inclusion criteria: Tumour diameter > 5 cm; tumour numbers ≤ 4; liver function of Child‐Pugh Class A and B; willing to sign a written informed consent document Exclusion criteria: Not suitable for TACE or MWA; with history of liver function or liver transplantation Age (mean ± SD, range): TACE + MWA: 58.74 ± 7.06 years, 35‐81 years; TACE alone: 58.26 ± 7.31 years, 34‐79 years Male (n/total): TACE + MWA: 43/62; TACE alone: 45/62
Interventions	TACE + MWA group (n = 62): TACE: Chemotherapeutic drugs: cisplatin 40‐60 mg and 5‐fluorouracil 0.75‐1 g MWA: The interval between TACE and RFA was 2‐4 weeks. Multiple sessions of MWA were performed with an interval of 2 weeks. TACE group (n = 62): Chemotherapeutic drugs: cisplatin 40‐60 mg and 5‐fluorouracil 0.75‐1 g
Outcomes	Tumour response: based on WHO criteria; measured at 4 weeks after treatment Survival rates
Notes	Country of study: China Source of funding: None There was insufficient information available to satisfactorily determine the method of randomisation and the study data could not be verified. We have attempted to contact the study authors for more information, but so far, we have not been successful in doing this.